Soluble transforming growth factor-β type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth

Circulation Research

Volumn 84, Issue 10, 1999, Pages 1212-1222

  Smith, Joshua D ^a   Bryant, Shane R ^a   Couper, Leslie L ^a   Vary, Calvin P H ^a   Gotwals, Philip J ^b   Koteliansky, Victor E ^b   Lindner, Volkhard ^a  

^a Maine Medical Center Research Institute   (United States)

^b BIOGEN   (United States)

Author keywords

Collagen; Fibrosis; Intimal hyperplasia; Myofibroblast; Smooth muscle actin

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; FC RECEPTOR; ISOPROTEIN; MESSENGER RNA; RECEPTOR SUBTYPE; RECOMBINANT RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL DIFFERENTIATION; COMMON CAROTID ARTERY; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBROBLAST; FIBROSIS; HISTOPATHOLOGY; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RAT; RNA ANALYSIS; TISSUE DISTRIBUTION; TISSUE GROWTH; TISSUE REPAIR; VASCULAR SMOOTH MUSCLE;

EID: 0033612364     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.84.10.1212     Document Type: Article

References (57)

1. Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation. 1994;89:2809-2815.
2. Lafont AM, Chisolm GM, Whitlow PL, Goormastic M, Cornhill JF. Post-angioplasty restenosis in the atherosclerotic rabbit: proliferative response or chronic constriction? Circulation. 1993;88(suppl I):I-521.
3. Nunes GL, Sgoutas DS, Redden RA, Sigman SR, Gravanis MB. Combination of vitamins C and E alters the response to coronary balloon injury in the pig. Arterioscler Thromb Vasc Biol. 1995;15:156-165.
4. Mintz GS, Kovach JA, Javier SP, Ditrano CJ, Leon MB. Geometric remodeling is the predominant mechanism of late lumen loss after coronary angioplasty. Circulation. 1993;88(suppl I):I-654.
5. Mintz G, Popma J, Pichard A, Kent K, Satler L. Mechanisms of late arterial responses to transcatheter therapy: a serial quantitative angiographic and intravascular ultrasound study. Circulation. 1994;90(suppl I):I-24.
6. Halloran BG, Prorok GD, So BJ, Baxter BT. Transforming growth factor-β1 inhibits human arterial smooth-muscle cell proliferation in a growth-rate-dependent manner. Am J Surg. 1995;170:193-197.
7. Mii S, Ware JA, Kent KC. Transforming growth factor-beta inhibits human vascular smooth muscle cell growth and migration. Surgery. 1993;114:464-470.
8. 1. J Clin Invest. 1995;96: 2667-2675.
9. 2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase. Biochem J. 1994;299:227-235.
10. Reddy KB, Howe PH. Transforming growth factor beta 1-mediated inhibition of smooth muscle cell proliferation is associated with a late G1 cell cycle arrest. J Cell Physiol. 1993;156:48-55.
11. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990;63:515-524.
12. Stouffer GA, Owens GK. TGF-β promotes proliferation of cultured SMC via both PDGF-AA-dependent and PDGF-AA-independent mechanisms. J Clin Invest. 1994;93:2048-2055.
13. Koyama N, Koshikawa T, Morisaki N, Saito Y, Yoshida S. Bifunctional effects of transforming growth factor-β on migration of cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1990;169:725-729.
14. 1 during repair of arterial injury. J Clin Invest. 1991;88:904-910.
15. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L. Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions. J Clin Invest. 1992;90:1582-1592.
16. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J Clin Invest. 1994;93:1172-1178.
17. Schulick AH, Taylor AJ, Zuo W, Qiu CB, Dong G, Woodward RN, Agah R, Roberts AB, Virmani R, Dichek DA. Overexpression of transforming growth factor beta 1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci U S A. 1998;95: 6983-6988.
18. Perrella MA, Patterson C, Tan L, Yet SF, Hsieh CM, Yoshizumi M, Lee ME. Suppression of interleukin-1beta-induced nitric-oxide synthase promoter/enhancer activity by transforming growth factor-beta 1 in vascular smooth muscle cells: evidence for mechanisms other than NF-κB. J Biol Chem. 1996;271:13776-13780.
19. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Hamaoki M, Kato H, Yazaki Y. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun. 1989;159:1435-1440.
20. Herbert JM, Carmeliet P. Involvement of u-PA in the anti-apoptotic activity of TGF-β for vascular smooth muscle cells. FEBS Lett. 1997; 413:401-404.
21. Ward MR, Agrotis A, Kanellakis P, Dilley R, Jennings G, Bobik A. Inhibition of protein tyrosine kinases attenuates increases in expression of transforming growth factor-beta isoforms and their receptors following arterial injury. Arterioscler Thromb Vasc Biol. 1997;17:2461-2470.
22. 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am J Respir Cell Mol Biol. 1996;14:131-138.
23. Pelton RW, Johnson MD, Perkett EA, Gold LI, Moses HL. Expression of transforming growth factor-beta 1, -beta 2, and -beta 3 mRNA and protein in the murine lung. Am J Respir Cell Mol Biol. 1991;5:522-530.
24. Bray P, Agrotis A, Bobik A. Transforming growth factor-beta and receptor tyrosine kinase-activating growth factors negatively regulate collagen genes in smooth muscle of hypertensive rats. Hypertension. 1998;31:986-994.
25. Heimark RL, Twardzik DR, Schwartz SM. Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science. 1986;233:1078-1080.
26. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
27. di Clemente N, Wilson C, Faure E, Boussin L, Carmillo P, Tizard R, Picard JY, Vigier B, Josso N, Cate R. Cloning, expression, and alternative splicing of the receptor for anti-mullerian hormone. Mol Endocrinol. 1994;8:1006-1020.
28. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med. 1993;178: 211-222.
29. Lindner V, Reidy MA. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries: an en face study. Circ Res. 1993;73:589-595.
30. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res. 1993;73:792-796.
31. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
32. Majesky MW, Reidy MA, Bowen Pope DF, Hart CE, Wilcox JN, Schwartz SM. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol. 1990;111:2149-2158.
33. Tsuchida K, Lewis KA, Mathews LS, Vale WW. Molecular characterization of rat transforming growth factor-β type II receptor. Biochem Biophys Res Commun. 1993;191:790-795.
34. Lopez-Casillas F, Payne HM, Andres JL, Massagué J. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol. 1994;124:557-568.
35. Cheifetz S, Hernandez H, Laiho M, Ten Dijke P, Iwata KK, Massagué J. Distinct transforming growth factor-β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J Biol Chem. 1990;265:20533-20538.
36. Taguchi J, Murry CE, Herren BI, Pech M, Schwartz SM, Lindner V. A quantitative method for determination of endothelial mRNA expression in vivo: induction of platelet-derived growth factor by endotoxin. Am J Pathol. 1998;152:903-912.
37. Orlandi A, Ropraz P, Gabbiani G. Proliferative activity and α-smooth muscle actin expression in cultured rat aortic smooth muscle cells are differently modulated by transforming growth factor-β1 and heparin. Exp Cell Res. 1994;214:528-536.
38. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122:103-111.
39. Verbeek MM, Otte-Holler I, Wesseling P, Ruiter DJ, de Waal RM. Induction of α-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-β1. Am J Pathol. 1994;144: 372-382.
40. Darby I, Skalli O, Gabbiani G. α-Smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest. 1990;63:21-29.
41. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92:1686-1696.
42. Tsang ML, Zhou L, Zheng BL, Wenker J, Fransen G, Humphrey 3, Smith JM, O'Connor-McCourt M, Lucas R, Weatherbee JA. Characterization of recombinant soluble human transforming growth factor-beta receptor type II (rhTGF-β sRII). Cytokine. 1995;7:389-397.
43. Mango V, Volpin D, Bressan GM. Regulation of the human elastin promoter in chick embryo cells: tissue-specific effect of TGF-β. Biochim Biophys Acta. 1993;1172:31-36.
44. Yamamoto H, Ueno H, Ooshima A, Takeshita A. Adenovirus-mediated transfer of a truncated transforming growth factor-beta (TGF-β) type II receptor completely and specifically abolishes diverse signaling by TGF-β in vascular wall cells in primary culture. J Biol Chem. 1996;271: 16253-16259.
45. Majesky MW, Schwartz SM, Clowes MM, Clowes AW. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ Res. 1987;61:296-300.
46. Perlman H, Maillard L, Krasinski K, Walsh K. Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation. 1997;95:981-987.
47. Lindner V. Role of basic fibroblast growth factor and platelet-derived growth factor (B-chain) in neointima formation after arterial injury. Z Kardiol. 1995;84(suppl 4):137-144.
48. Matzner Y, Vlodavsky I, Michaeli RI, Eldor A. Selective inhibition of neutrophil activation by the subendothelial extracellular matrix: possible role in protection of the vessel wall during diapedesis. Exp Cell Res. 1990;189:233-240.
49. Lindner V, Collins T. Expression of NF-κB and IκB-α by aortic endothelium in an arterial injury model. Am J Pathol. 1996;148:427-438.
50. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol. 1989;109:309-315.
51. Gleizes PE, Munger JS, Nunes I, Harpel JG, Mazzieri R, Noguera I, Rifkin DB. TGF-β latency: biological significance and mechanisms of activation. Stem Cells. 1997;15:190-197.
52. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol. 1993;122:923-932.
53. 1 in vivo. Cell. 1998;93:1159-1170.
54. Jackson CL, Reidy MA. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann N Y Acad Sci. 1992;667: 141-150.
55. Majack RA, Cook SC, Bornstein P. Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. J Cell Biol. 1985;101: 1059-1070.
56. Raugi GJ, Mullen JS, Bark DH, Okada T, Mayberg MR. Thrombospondin deposition in rat carotid artery injury. Am J Pathol. 1990;137:179-185.
57. Miano JM, Vlasic N, Tota RR, Stemerman MB. Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury: a putative in vivo mechanism for autocrine growth. Arterioscler Thromb. 1993;13:211-219.